The recognition of distinct forms of CPVT with diverse etiologies such as dominant mutations in RyR2 or recessive mutations in CASQ2 mark a pivotal advancement in embracing rapidly evolving precision medicine strategies, showcasing promising efficacy in experimental models [27]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.